Skip to content
Psychiatrist.com Logo
  • JCP
  • PCC
  • News
  • CME
  • About
  • Authors & Reviewers
  • Sign In
  • Subscribe
Advanced Search

Menu

  • JCP
  • PCC
  • News
  • CME
  • About
  • Authors & Reviewers
  • Sign In
  • Subscribe
Sign in Subscribe

Clinical Topics

View All
  • Addiction
  • ADHD
  • Alzheimer’s Disease
  • Anxiety
  • Bipolar Disorder
  • Depression
  • Movement Disorders
  • Neurology
  • OCD
  • Psychopharmacology
  • PTSD and Trauma
  • Schizophrenia/Schizoaffective Disorders
  • Sleep
  • Tardive Dyskinesia
  • View All

Collections

View All
  • Academic Highlights
  • Auvelity: Information from Industry
  • Banner Alzheimer’s Institute
  • Clinical & Practical Psychopharmacology
  • Early Career Psychiatrists
  • Focus on Childhood and Adolescent Mental Health
  • Focus on Geriatric Psychiatry
  • Focus on Psychotherapy
  • Focus on Suicide
  • Focus on Psychosis
  • Focus on Women’s Mental Health
  • Rounds in the General Hospital
  • UZEDY: Information from Industry
  • View All
Back to top Open menu arrow
Download PDF Reprints
No sections available

The Journal of
Clinical Psychiatry

Free access
Bipolar Disorder

Letter to the Editor August 1, 2001

Reboxetine-Induced Hypomania

Eduard Vieta; Francesc Colom; Cristóbal Gastó; Anabel Martínez-Arán; María Reinares; Antonio Benabarre; Barbara Corbella

J Clin Psychiatry 2001;62(8):655-656

Article Abstract

Letter to the Editor

Reboxetine-Induced Hypomania

 

About the Authors

  • Eduard Vieta
    View full profile
  • Francesc Colom
    View full profile
  • Cristóbal Gastó
    View full profile
  • Anabel Martínez-Arán
    View full profile
  • María Reinares
    View full profile
  • Antonio Benabarre
    View full profile
  • Barbara Corbella
    View full profile
Download Free PDF

This PDF is free for all visitors!

Related News Articles

Smart Patch Offers Breakthrough in Bipolar Disorder Monitoring How Patients Talk May Matter More Than What They Say AI Predicts Schizophrenia Using Patient Records
Announcement: The Journal of Clinical Psychiatry launches a new podcast. Click to learn more.

Related JCP Articles

Suicidality in Postpartum Women with Unipolar and Bipolar Depression Triple Network Model–Based Functional Dysconnectivity in Young People With Major Affective Disorders With or Without Suicidal Ideation Prevalence and 3-Year Outcomes of Mood Disorders

Related PCC Articles

Imipramine-Induced Catatonia Bipolar Disorder Preceding PTC Diagnosis Readability of Bipolar Disorder Measures
Cover of The Journal of Clinical Psychiatry, September 2025 issue, featuring article titles on postpartum distress, aripiprazole monohydrate injectables for schizophrenia and bipolar disorder, and other psychiatric topics.

Vol 86 • 2025 • Number 3

Read the Current Issue

Original Research

Postpartum Distress in Women With and Without ADHD

Academic Highlights

Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Schizophrenia: A Consensus Panel Report

Academic Highlights

Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Bipolar Type I Disorder: A Consensus Panel Report

In Memoriam

In Memoriam: Terence A. Ketter, MD

Narrative Review

Idiopathic Hypersomnia: Recognition and Management in Psychiatric Practice

Original Research

Predictors of Treatment Response to Adjunctive VNS Therapy in Major Depressive Disorder: A RECOVER Trial Report

View current Issue

Related Articles

JCP
Letter to the Editor

Antidepressant Effects of Combined Mood Stabilizers May Account for High Placebo Response Rates

June 22, 2021

Dr Terao comments on the methodology of a recent study evaluating citalopram for bipolar depression.
Takeshi Terao
JCP
Letter to the Editor

Antidepressants Added Nothing to Mood Stabilizers Alone: Reply to Terao

June 22, 2021

Dr Ghaemi responds to Dr Terao’s letter regarding a study of citalopram for bipolar depression.
S. Nassir Ghaemi
JCP
Letter to the Editor

Adjunctive Mood Stabilizers Are Not the Same As a Placebo-Only Arm in Bipolar Depression Trials: Reply to Terao

June 22, 2021

Dr Goldberg responds to Dr Terao’s letter regarding a study of citalopram for bipolar depression.
Joseph F. Goldberg

Consensus Report on XT Use in Practice

Figure: Graphic promoting Consensus Report on Xanomeline-Trospium; colorful net design shown with JCP logo in lower left.

Subscribe to read
more articles

Subscribe
The Journal of Clinical Psychiatry
The Primary Care Companion for CNS Disorders

ELSEWHERE:

  • ABOUT
  • ADVERTISERS
  • MEDIA RELATIONS
  • REPRINTS & PERMISSIONS
  • CONTACT US
  • CUSTOMER SUPPORT

FOLLOW US:

  • X
  • FACEBOOK
  • INSTAGRAM
  • LINKEDIN
  • THREADS
  • BLUESKY
  • SIGN IN

  • JOIN THE EMAIL LIST


SUBSCRIBE NOW
An image of the Psychiatrist.com logo mark
  • Privacy Policy
  • Terms of Use
  • Physicians Postgraduate Press, Inc.
  • JCP ISSN: Online 1555-2101, Print 0160-6689
  • PCC ISSN: Online 2155-7780, Print 2155-7772
  • MedFair.com US Patent No. 684794
  • © Copyright 2025 | Physicians Postgraduate Press, Inc. | LifeLong Learning For Clinicians
  • Sitemap